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P40% to 50% range, so there is a decrement even in the treated
animals. They do have an 8% infarct and they are just status
post–significant ischemic injury. So we don’t necessarily expect
them to get back to a baseline level, but it’s mostly the difference
between the 2 groups that we’re looking at.
Dr Vinten-Johansen. You gave the injections or the adminis-
trations at ischemia and reperfusion to take advantage of both the
metabolic effects as well as the antioxidant effects, is that the
rationale?The Journal of ThoracicDr Vinten-Johansen. How did you decide on the dosage, the
concentration that you gave?
Dr Woo. We were guided somewhat by the intestinal ischemic-
reperfusion work, although that’s just a starting point. There is no
dose-dependent evaluation of ethyl pyruvate in the literature for
any of the other trauma critical care work. There are only maybe
5 published studies, period, looking at anything physiologic.
In terms of pyruvate, there is a dose-dependent benefit. So we
could potentially shoot for an equimolar concentration of pre-Dr Woo. That’s right. sumed pyruvate release as another target point.and Cardiovascular Surgery ● Volume 127, Number 5 1269
